Catalent adds Micron Technologies to portfolio

Catalent has acquired Micron Technologies, adding a specialist in particle size engineering to its combined offering.

The Catalent brand will now carry products such as OptiForm API optimisation and Micron Technologies' particle size optimisation, formulation and final dose form design services as well as bioavailability products including RP Scherer Softgel lipid systems and OptiMelt hot melt extrusion technologies.

“This strategic acquisition allows Catalent to provide an unprecedented set of integrated development solutions and superior drug delivery technologies to the industry, partnering with our customers’ R&D teams earlier in the development cycle and helping them deliver better treatments to clinic and to market faster and more efficiently,” said John Chiminski, Catalent, Inc. President and CEO. “We are pleased to add Micron Technologies’ leading technologies and manufacturing expertise and welcome their highly talented management, scientific and operations teams to Catalent.”

The acquisition is Catalent’s second since its IPO in July, and follows the acquisition of Redwood Bioscience, with its SMARTag Antibody-Drug Conjugate (ADC) technology platform, in October 2014. 

Joseph Drost, CEO of Micron Technologies, who will continue to lead this business, said: “We are excited to become part of Catalent, as there is a natural synergy between our organisations, with the global leader in advanced delivery technologies and development solutions now joining forces with a leading provider of particle size engineering technologies and integrated analytical services. Through access to Catalent’s global network, development expertise and innovative technologies, we can jointly provide end-to-end solutions to accelerate drug development programs and bring better treatments to patients worldwide.”